JP2024546654A5 - - Google Patents

Info

Publication number
JP2024546654A5
JP2024546654A5 JP2024533810A JP2024533810A JP2024546654A5 JP 2024546654 A5 JP2024546654 A5 JP 2024546654A5 JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024546654 A5 JP2024546654 A5 JP 2024546654A5
Authority
JP
Japan
Prior art keywords
syndrome
disease
cancer
autoimmune
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081186 external-priority patent/WO2023108073A2/en
Publication of JP2024546654A publication Critical patent/JP2024546654A/ja
Publication of JP2024546654A5 publication Critical patent/JP2024546654A5/ja
Pending legal-status Critical Current

Links

JP2024533810A 2021-12-10 2022-12-08 ポリペプチドモジュレーター Pending JP2024546654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288330P 2021-12-10 2021-12-10
US63/288,330 2021-12-10
PCT/US2022/081186 WO2023108073A2 (en) 2021-12-10 2022-12-08 Polypeptide modulators

Publications (2)

Publication Number Publication Date
JP2024546654A JP2024546654A (ja) 2024-12-26
JP2024546654A5 true JP2024546654A5 (cg-RX-API-DMAC7.html) 2025-12-16

Family

ID=86731448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533810A Pending JP2024546654A (ja) 2021-12-10 2022-12-08 ポリペプチドモジュレーター

Country Status (10)

Country Link
US (1) US20250051419A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444339A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546654A (cg-RX-API-DMAC7.html)
KR (1) KR20240118832A (cg-RX-API-DMAC7.html)
CN (1) CN118613277A (cg-RX-API-DMAC7.html)
AU (1) AU2022405109A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241913A1 (cg-RX-API-DMAC7.html)
IL (1) IL313360A (cg-RX-API-DMAC7.html)
MX (1) MX2024006897A (cg-RX-API-DMAC7.html)
WO (1) WO2023108073A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026519808A (ja) * 2023-06-06 2026-06-18 ジョージアミューン・インコーポレイテッド 新規pd-l2変異体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000692A2 (en) * 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN106794235A (zh) * 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
US11219694B2 (en) * 2015-09-24 2022-01-11 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
JP2020511144A (ja) * 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3908600A1 (en) * 2019-01-11 2021-11-17 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Fusion protein with immunosuppressive activity

Similar Documents

Publication Publication Date Title
ES2948647T3 (es) Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
ES3058927T3 (en) Cell-penetrating peptide conjugates and methods of their use
JP2010518006A5 (cg-RX-API-DMAC7.html)
JP7564087B2 (ja) アンチセンス送達のための三量体ペプチド
JP2025032075A (ja) Baff-r二重特異性t細胞エンゲージャー抗体
JP2020513855A5 (cg-RX-API-DMAC7.html)
RU2009114161A (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
CN113905744A (zh) 经修饰的间隙子寡核苷酸及其使用方法
JP2002505309A (ja) 腫瘍治療のための組成物および方法
EP3271395A1 (en) Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof
ES2401822T3 (es) Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR
AU2024259837B2 (en) ADP-ribose binding peptide having anticancer activity and use thereof
CN102633883A (zh) 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
CN121943909A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
ES2277683T3 (es) Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico.
WO2023196876A1 (en) Il-7ralpha-gamma ligand immunoglobulin fusion proteins
WO2020041691A9 (en) Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and uses thereof
CN120437288A (zh) 治疗卵巢癌的药物组合
JP2025515191A5 (cg-RX-API-DMAC7.html)
JP2024542096A5 (cg-RX-API-DMAC7.html)
Li et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment
AU2022341787A1 (en) Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy
WO2025087363A1 (zh) 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法
JP2024546654A (ja) ポリペプチドモジュレーター
US12043673B2 (en) Complementary RNA linked bispecific T-cell engaging antibodies